Cysteine Hydrochloride
CAS 52-89-1
Cysteine Hydrochloride (CAS 52-89-1) is a Phase 4 pharmaceutical compound with 0 bioactivity targets and 0 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| Cysteine Hydrochloride | 221086 | SU | MTHSPL |
| CYSTEINE HYDROCHLORIDE | 221086 | SU | MTHSPL |
| cysteine hydrochloride | 221086 | PIN | RXNORM |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Cysteine Hydrochloride used for in pharmaceutical contexts?
Cysteine Hydrochloride (CAS 52-89-1) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Cysteine Hydrochloride?
Cysteine Hydrochloride has 0 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Body temperature decreased, Prostatic specific antigen increased, Retching. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Cysteine Hydrochloride also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for CYSTEINE HCL with EU status "permitted".
What clinical phase is Cysteine Hydrochloride in?
Cysteine Hydrochloride is rendered with ChEMBL max phase 4 (approved).